Book chapter
Chapter 11 - Therapeutic drug monitoring of selected antifungal agents
Therapeutic Drug Monitoring, pp.265-280
Academic Press, Second Edition
2024
DOI: 10.1016/B978-0-443-18649-3.00026-4
Abstract
This chapter provides an overview of therapeutic drug monitoring of selected antifungal drugs. The antifungal drugs with the strongest evidence for routine drug monitoring are the triazoles (particularly itraconazole, posaconazole, and voriconazole) and the antimetabolite 5-flucytosine. Justifications for drug monitoring include immunocompromized patients, variable pharmacokinetics, clearly defined correlation between drug concentration and therapeutic efficacy, and avoidance of toxicity. The benefit of drug monitoring is less certain for amphotericin B and the echinocandins such as caspofungin. Future areas for research include drug monitoring of antifungal agents in specialized populations such as young children (especially neonates in infants) and for combination antifungal therapy.
Details
- Title: Subtitle
- Chapter 11 - Therapeutic drug monitoring of selected antifungal agents
- Creators
- Matthew D. Krasowski - University of Iowa
- Resource Type
- Book chapter
- Publication Details
- Therapeutic Drug Monitoring, pp.265-280
- Edition
- Second Edition
- DOI
- 10.1016/B978-0-443-18649-3.00026-4
- Publisher
- Academic Press; London
- Language
- English
- Date published
- 2024
- Academic Unit
- Pathology
- Record Identifier
- 9984948118102771
Metrics
1 Record Views